Roche advances its open diabetes management ecosystem by integrating continuous glucose monitoring data to drive personalised therapy decisions
- The expansion of the partnership with Senseonics is the next step in integrating the long-term Eversense® Continuous Glucose Monitoring (CGM) system with Roche's suite of digital diabetes management solutions.
- People with diabetes and their physicians will be able to view real-time glucose information and related data both on Roche's apps and web-based solutions in addition to the Eversense app.
- This integration will unlock data access for users to a consolidated view of therapy-relevant information, thus supporting improved therapy decisions.
BASEL, Switzerland, Sept. 26, 2018 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has signed a non-exclusive data integration agreement with Senseonics Incorporated, expanding its partnership. Under the terms of the agreement, both partners aim to implement the next step in data integration of the long-term Eversense Continuous Glucose Monitoring (CGM) system with Roche's suite of digital diabetes management solutions. This integration will allow for the real-time CGM data to be synchronised so Eversense users and their physicians will be able to review glucose values as well as related data online and on their mobile phones e.g. via the mySugr app or Accu-Chek Smart Pix. The initial data integration is planned to be available to users beginning 2019.
"Expanding our longstanding relationship with Senseonics by incorporating data generated via the Eversense and Eversense XL CGM sensors into our digital solutions is an important step in moving our open ecosystem forward. Doing so, we continue to embrace our vision to bring innovation by means of truly integrated diabetes management solutions to the market, empowering people with diabetes to confidently manage their therapy routines every day and helping them experience true relief," says Marcel Gmuender, Global Head of Roche Diabetes Care.
"Partnering with Roche and being part of its open ecosystem for personalised diabetes management is a good fit with our strategy of giving people with diabetes the tools to use valuable health data for making actionable and informed therapy decisions," states Dr. Tim Goodnow, President and, CEO of Senseonics.
About Roche Diabetes Care
Roche Diabetes Care is pioneering innovative diabetes technologies and services since more than 40 years. Being a global leader in integrated diabetes management, more than 5,000 employees in over 100 markets worldwide work every day to support people with diabetes and those at risk to achieve more time in their target range and experience true relief from the daily therapy routines. Roche Diabetes Care collaborates with caregivers, healthcare providers and payers to optimally manage this complex condition and contribute to sustainable care structures. Under the brand Accu-Chek and in collaboration with partners, Roche Diabetes Care creates value by providing integrated solutions to monitor glucose levels, deliver insulin and track as well as contextualize relevant data points for a successful therapy. By establishing a leading open ecosystem, connecting devices, digital solutions, Roche Diabetes Care will enable optimal personalised diabetes management and thus improve therapy outcomes. Since 2017, mySugr with its world leading mobile diabetes management app and services is part of Roche Diabetes Care. For more information please visit www.accu-chek.com and www.mysugr.com.
About Roche
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people's lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry ten years in a row by the Dow Jones Sustainability Indices (DJSI). The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2017 employed about 94,000 people worldwide. In 2017, Roche invested CHF 10.4 billion in R&D and posted sales of CHF 53.3 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.
For more information please contact:
- Ute Volkmann (ute.volkmann@roche.com)
- Soo-Jin Pak (soo-jin.pak@roche.com)
Logo - https://mma.prnewswire.com/media/709962/Roche_Logo.jpg
Share this article